Visiopharm

Visiopharm is a world leader in AI-driven digital precision pathology software. The company, founded in 2002, offers AI-driven precision pathology software for research and diagnostics. In the research sector, Visiopharm provides tools for scientists, pathologists, and image analysis experts to produce accurate data for various tissue-based research. In the diagnostics arena, the company is a leader in clinical applications, with eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and can be easily integrated into existing lab workflows. Based in Denmark, Visiopharm operates internationally with over 750 customer accounts in more than 40 countries. The company has headquarters in Denmark’s Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States. Additionally, it has local representation in France and China. Their last investment, a Venture Round investment at 01 September 2020, saw participation from Northcap, BankInvest Group, Vaekstfonden, ATP, and C.L. Davids Fond. As a leading player in the Health Care industry, Visiopharm continues to expand its presence and offerings in the global market.